The U.S. FDA issued clearances for Medtronic’s Hugo robotic‑assisted surgery (RAS) system and CMR Surgical’s Versius Plus system, adding two competitors to the U.S. soft‑tissue surgical robotics market long dominated by Intuitive Surgical. The approvals expand procurement choices for hospitals and could intensify price and adoption dynamics. Both systems aim to lower barriers to robotic surgery through modular designs and flexible OR integrations. The new entrants may accelerate hospital negotiations, training programs and platform consolidation decisions as health systems weigh capital budgets and service line strategies.